MedAvail (MDVL) Stock Forecast, Price & News

MedAvail (NASDAQ:MDVL) Frequently Asked Questions

Is MedAvail a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MedAvail in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MedAvail stock.
View analyst ratings for MedAvail or view top-rated stocks.

How were MedAvail's earnings last quarter?

MedAvail Holdings, Inc. (NASDAQ:MDVL) posted its quarterly earnings results on Thursday, March, 24th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.04. MedAvail had a negative net margin of 198.00% and a negative trailing twelve-month return on equity of 121.31%. During the same period in the previous year, the business posted ($0.57) earnings per share.
View MedAvail's earnings history.

What guidance has MedAvail issued on next quarter's earnings?

MedAvail issued an update on its first quarter 2022 earnings guidance on Thursday, April, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $8.80 M-, compared to the consensus revenue estimate of $7.64 million.

What price target have analysts set for MDVL?

2 analysts have issued 1-year price objectives for MedAvail's shares. Their forecasts range from $8.00 to $9.50. On average, they expect MedAvail's stock price to reach $8.75 in the next year. This suggests a possible upside of 430.3% from the stock's current price.
View analysts' price targets for MedAvail or view top-rated stocks among Wall Street analysts.

Who are MedAvail's key executives?

MedAvail's management team includes the following people:

• Mr. Ryan Ferguson, Consultant (Age 47, Pay $389.7k)
• Mr. Mark Doerr RPh, CEO & Director
• Ms. Ramona Seabaugh, Chief Financial Officer
• Mr. George Burrows, VP of Operations & Vendor Management
• Matt Broome, Exec. VP & GM of Technology
• Mr. Craig Holtgrave, Sr. VP of Sales & Marketing
• Ms. Lisa Lutich, Chief HR Officer
• Ms. Joan O'Rourke, Pres of SpotRx
• Mr. Steven B. Hess R.Ph., Exec. VP & GM of SpotRx
• Mr. Bob McClune, Sr. VP of Data & Analytics

Who are some of MedAvail's key competitors?

Some companies that are related to MedAvail include 111 (YI), General Cannabis (CANN), Progressive Care (RXMD), HealthWarehouse.com (HEWA), China Jo-Jo Drugstores (CJJD), China Dasheng Biotechnology (CDBT), Dougherty's Pharmacy (MYDP), Dragon Jade International (DGJI) and Health Sciences Group (HESG).
View all of MDVL's competitors.

What is MedAvail's stock symbol?

MedAvail trades on the NASDAQ under the ticker symbol "MDVL."

Who are MedAvail's major shareholders?

MedAvail's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Alyeska Investment Group L.P. (22.88%), BlackRock Inc. (1.63%), Vanguard Group Inc. (1.62%), State Street Corp (0.67%), Joel Isaacson & Co. LLC (0.06%) and Belvedere Trading LLC (0.00%).
View institutional ownership trends for MedAvail.

Which institutional investors are selling MedAvail stock?

MDVL stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., State Street Corp, BlackRock Inc., and Joel Isaacson & Co. LLC.
View insider buying and selling activity for MedAvail or view top insider-selling stocks.

Which institutional investors are buying MedAvail stock?

MDVL stock was acquired by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., and Belvedere Trading LLC.
View insider buying and selling activity for MedAvail or or view top insider-buying stocks.

How do I buy shares of MedAvail?

Shares of MDVL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MedAvail's stock price today?

One share of MDVL stock can currently be purchased for approximately $1.65.

How much money does MedAvail make?

MedAvail has a market capitalization of $54.30 million and generates $22.13 million in revenue each year. The company earns $-43.81 million in net income (profit) each year or ($1.33) on an earnings per share basis.

How many employees does MedAvail have?

MedAvail employs 287 workers across the globe.

What is MedAvail's official website?

The official website for MedAvail is www.medavail.com.

How can I contact MedAvail?

MedAvail's mailing address is 45 HORSEHILL ROAD SUITE 106, CEDAR KNOLLS NJ, 07927. The company can be reached via phone at (905) 812-0023, via email at [email protected], or via fax at 973-348-5707.